The global research antibodies market size was valued at USD 2.52 billion in 2016. It is anticipated to progress at a CAGR of 6.1% over the forecast period. There has been a rise in number of R&D activities led by various biopharmaceutical and pharmaceutical companies to develop innovative products. The factor has helped the market to gain tremendous traction.
Growing investments in R&D activities is expected to spur the demand for research antibodies. For instance, in 2016, Novartis invested USD 9.0 billion in R&D, whereas Pfizer invested USD 7.9 billion in the same year for the development of novel products and technologies.
Furthermore, increasing prevalence of cancer and other chronic diseases is encouraging academic institutes as well as pharmaceutical and biotechnology companies to develop advanced generation therapeutics and personalized medicines. This is one of the key trends stimulating market growth. Usage of research antibodies in early detection of cancer has also been gaining recognition in the medical industry.
Presence of public & private initiatives and funds to promote stem cell studies is augmenting growth prospects. CIRM’s funding of USD 271.0 million for stem cell studies created 12 R&D spaces in California, which further brought in approximately USD 543.0 million funding for stem cell studies. Stem cell studies are also funded by the National Institutes of Health (NIH) that invested approximately USD 1.43 billion in 2015.
The primary segment held the dominant share of the market in 2016. The segment is also poised to exhibit remarkable CAGR during the forecast period. The growth of the segment can be attributed to increasing adoption of reagents containing primary research antibodies due to its associated benefits such as easy availability, greater specificity, and suitability to various research needs.
High significance in therapeutics of several chronic diseases such as cancer, diabetes, Alzheimer’s disease, and Parkinson’s disease are revving up the adoption rate of research antibodies. Moreover, availability of wide range of primary antibodies (Abs) such as conjugated, validated, recombinant, and flow cytometry versions is supplementing the growth of the segment.
The secondary segment is estimated to register a steady growth rate over the coming years. Secondary Abs are highly convenient and economical to develop as well as are available in ready - to - use form as reagents, which is likely to raise their demand in the coming years. These Abs aid in sorting, detection as well as purification of target antigens, thus enhancing the efficiency of product development activities.
Monoclonal antibodies accounted for the leading share in 2016. Significant rise in the number of research activities in genomics that require technologically advanced genetic platforms has led to surge in the demand for monoclonal antibodies. Monoclonal antibodies hold high importance in the identification of small groups such as acetyl, phosphor, methyl, or other groups that are critical during research procedures.
The polyclonal antibodies segment is projected to post healthy growth rate during the forecast period. Polyclonal antibodies are relatively inexpensive as compared to their counterparts, which is anticipated to escalate their adoption in low - budget and non - funded research projects.
Their other advantages include high stability, tolerance, greater affinity, suitability to various technologies such as sandwich ELISA, and easy storage. These benefits are expected to present the segment with considerable growth opportunities. In addition, they possess high sensitivity in detection of proteins present in low quantities, thus boosting inclination of clinical researchers towards polyclonal antibodies.
On the basis of technology, western blotting was the leading revenue contributor to the market in 2016. Growing prevalence of diseases with limited treatment options such as HIV is driving the growth of the segment. Western blot is increasingly being preferred to other technologies such as enzyme - linked immunosorbent assay (ELISA) tests owing to greater accuracy.
Western blotting is widely used in research activities conducted by academic institutes as well as pharmaceutical and biotechnology companies. Moreover, growing number of government initiatives to pool funds to support these activities are leading to phenomenal upsurge in adoption.
Immunohistochemistry (IHC) commanded the second largest share of the market in 2016. The considerable share attained by this segment is a result of IHC regarded as one of the critical steps to facilitate researchers in initial stages of research. This technology is extensively used in cancer studies and is expected to experience noteworthy CAGR during the forecast period owing to unprecedented increase in cancer prevalence.
Based on source, mouse was the most prominent segment in 2016. The dominance of the segment can be attributed to its stability in and suitability for in - vitro and in - vivo studies. Mouse monoclonal and polyclonal Abs are relatively easier to produce and possess relevant specificity. Technological upgradation in development process of mouse Abs, such as adoption of hybridoma technology that produces monoclonal antibodies (MAbs) in specialized cells, are further propelling the growth of the segment.
Rabbit Abs are poised to witness considerable growth opportunities over the coming years. The growing preference is due to the fact that rabbit immune system possesses higher affinity, approximately 10 to 100 - fold greater than mouse Abs. Moreover, rabbit immune system is suitable in generation of Abs that is capable of distinguishing molecules with similar structures.
The goat segment is estimated to witness steady growth during the forecast period. The steady rate can be attributed to preference for goat as animal source for large - scale production. In addition, its cost - effectivity is suitable for most large - scale projects.
Oncology was the dominant application segment in 2016 owing to unprecedentedly growing cancer afflicted population. According to WHO, the number of new cancer cases is likely to increase by approximately 70.0% in coming years. In addition, cancer is the second leading cause of mortality rates, thus supporting high clinical urgency to expedite research & diagnosis for cancer.
Key players such as Merck Millipore have dedicated antibodies for cancer and study of different stages of cancer such as apoptosis, autophagy, angiogenesis, and metastasis. Abs adopted in cancer research and diagnosis facilitates generation of reliable output data from proteomic, genomic, and epigenomic studies, which are crucial for disease progression studies.
The stem cells segment is projected to witness exponential growth rate throughout the forecast period. Research Abs aid in specific and live cell immuno staining of different stem cells such as adult, embryonic, and pluripotent stem cells. Moreover, cell isolation and cell culture applications are further anticipated to foster growth prospects of the segment.
Pharmaceutical & biotechnology companies were at the forefront of the market in 2016. Abs are extensively used along with other consumables during product development stages in these companies. In addition, academic and research institutes will also hold a prominent place in the market, owing to presence of various academic groups involved in the study of complex biological systems using advanced reagents.
Rising demand for quality control in areas of PCR, epigenetics, and electrophoresis are expected to boost the adoption of Abs further during the forecast period. Moreover, increasing funding in public and private organizations is poised to further trigger the growth of the market.
Contract outsourcing organizations (CROs) are estimated to exhibit an exponential CAGR during the forecast period owing to growing popularity of contract services among pharma and biotechnology companies. Benefits offered by contract services include cost advantages, higher efficiency of services, enhanced productivity, and higher focus on core areas of development, which are critical for a company’s growth.
North America was the leading regional market in 2016. Presence of a large number of biotechnology & biopharmaceutical manufacturers and academic institutes coupled with huge economic development are some of the key factors propelling the North America research antibodies market. In addition, antibody production guidelines issued by public organizations are ensuring high quality products, which are resulting in greater reliance of researchers and clinicians. This is, thereby, contributing to the growth of the region.
Asia Pacific is likely to register a remarkable CAGR throughout the forecast period. Increasing innovation in antibody production is projected to be responsible for new avenues for growth across this region. Moreover, improving healthcare infrastructure coupled with strengthening favorable regulatory policies implemented by public healthcare organizations to enhance safety is further anticipated to stir up the growth of the regional market.
Some of the key players in the market are Abcam PLC; Agilent Technologies; and Thermo Fisher Scientific, Inc. These companies are undertaking strategies to achieve high sustainability in the competitive environment. The market is moderately consolidated and highly competitive due to low entry barriers.
The registered growth in this sector is a consequence of undertaking extensive expansion strategies, new product development, geographical expansions, and mergers & acquisitions. For instance, in December 2017, PerkinElmer, Inc. announced the acquisition of EUROIMMUN Medical Laboratory Diagnostics AG. Similarly, In March 2016, the company completed the acquisition of Affymetrix, Inc. This acquisition was done to strengthen competitive position in the bioscience field and expand portfolio.
Base year for estimation
Actual estimates/Historical data
2014 - 2015
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, MEA
Revenue forecast, company share, competitive landscape, growth factors and trends
U.S., Canada, U.K., Germany, Japan, China, India, Mexico, Brazil, South Africa
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub - segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global research antibodies market report on the basis of product, type, technology, source, application, end - use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Type Outlook (Revenue, USD Million, 2014 - 2025)
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Source Outlook (Revenue, USD Million, 2014 - 2025)
Application Outlook (Revenue, USD Million, 2014 - 2025)
End - use Outlook (Revenue, USD Million, 2014 - 2025)
Academic & Research Institutes
Contract Research Organizations
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."